Biomarkers of subclinical atherosclerosis
OwnerEstefania NUNEZ SANCHEZ, Jesus VAZQUEZ COBOS +5inventors
InventorsEstefania NUNEZ SANCHEZ, Jesus VAZQUEZ COBOS, Valentin FUSTER, Diego MARTINEZ LOPEZ, Jose Luis MARTIN VENTURA, Elena BONZON KULICHENKO, Enrique CALVO ALCOCER
Life of this patent
Estimating the term…
Abstract
The present invention relates to PIGR, APOA, HPT, HEP2, C5, ITIH1 and IGHA2 as biomarkers for the screening, diagnosis and/or monitoring of subclinical atherosclerosis and methods and kits using thereof.
Claims21
A method for the screening, diagnosis and/or monitoring of subclinical atherosclerosis in a subject, wherein said method comprises:
- a) determining in a biological sample isolated from said subject the protein expression levels of:
- i. PIGR and/or IGHA2;
- and
- ii. optionally, one, two, three, four or five biomarkers, selected from APOA, HPT, HEP2, ITIH1 and C5;
- b) comparing the levels of the biomarkers with a reference value;
- c) wherein when the levels in the subject's sample of PIGR, IGHA2, APOA, HPT, HEP2 ITIH1 and/or C5 are increased with respect to the corresponding reference value is indicative of subclinical atherosclerosis.
Kit comprising reagents adequate for the determination of the protein expression levels of the following biomarkers:
- i. PIGR and/or IGHA2;
- ii. optionally, one, two, three, four or five biomarkers selected from APOA, HPT, HEP2, ITIH1 and C5;
- wherein said kit comprises:
- a. an affinity reagent for PIGR and/or IGHA2;
- b. optionally, an affinity reagent for one, two, three four or five of APOA, HPT, HEP2, ITIH1 and C5;
- c. optionally, further comprising instructions for the use of said reagents in determining said protein expression levels in a biological sample isolated from a subject.
(canceled)
Dependencies are inferred from the claim text.